Invesaro

Stocks Health care PDEX

NASDAQ · Health care

Pro Dex Inc (PDEX)

Pro Dex Inc reported revenue of $77.5M in fiscal 2026, up 16.5% from a year earlier. Net income was $13.7M, a net margin of 17.6%. Operating cash flow minus capital spending left $6.8M of free cash flow in fiscal 2026. At June 30, 2026 it held $8.2M in cash against $17.5M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on September 3, 2026.

Price
$71.77
-1.71% on the day · September 25, 2026
52-week range $23.47 to $77.00
Market cap
$229.1M
Revenue (FY2026)
$77.5M
+16.5% year on year
Net margin
17.6%
P/E
17.4
on FY2026 diluted EPS

What Pro Dex Inc does

Pro Dex Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PDEX.

Revenue and profit by year

Revenue
FY19: $27.2M $27.2M FY19FY20: $34.8M $34.8M FY20FY21: $38M $38M FY21FY22: $42M $42M FY22FY23: $46.1M $46.1M FY23FY24: $53.8M $53.8M FY24FY25: $66.6M $66.6M FY25FY26: $77.5M $77.5M FY26
Net income
FY19: $4.1M $4.1M FY19FY20: $6.1M $6.1M FY20FY21: $6.2M $6.2M FY21FY22: $4.6M $4.6M FY22FY23: $7.1M $7.1M FY23FY24: $2.1M $2.1M FY24FY25: $9M $9M FY25FY26: $13.7M $13.7M FY26

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2026$77.5M$13M$13.7M$4.12$6.8M
2025$66.6M$10.7M$9M$2.67-$2.9M
2024$53.8M$7.2M$2.1M$0.60n/a
2023$46.1M$5.8M$7.1M$1.95n/a
2022$42M$5.1M$4.6M$1.21-$2.5M
2021$38M$4.5M$6.2M$1.57-$3.8M
Next report expected around October 29, 2026.

Estimated from its filing rhythm: 52 weeks after its report of October 30, 2025. Not a date the company has announced. See the report calendar

Where PDEX ranks in Health care

Revenue$77.5M
#322 of 523 in Health care · Bottom 39%
Revenue growth+16.5%
#182 of 437 in Health care · Top 42%
Net margin17.6%
#57 of 447 in Health care · Top 13%
Free cash flow margin8.7%
#128 of 408 in Health care · Top 31%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Pro Dex Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 18, 2026
    Material agreement 8-K
  2. September 3, 2026
    Quarterly results 8-K
  3. September 3, 2026
    Annual report 10-K · period to June 30, 2026
  4. August 28, 2026
    Executive or director change 8-K
  5. June 26, 2026
    Activist stake changed SCHEDULE 13D/A
  6. June 17, 2026
    Investor disclosure 8-K
  7. June 1, 2026
    Conflict minerals disclosure SD
  8. April 30, 2026
    Quarterly results 8-K
  9. April 30, 2026
    Quarterly report 10-Q · period to March 31, 2026
  10. March 27, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 14, 2026. Insider transactions on SEC

What is PDEX worth? A DCF from its reported cash flow

Insider trades

What the people running Pro Dex Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $1.4M worth of shares in the last 90 days and bought none on the open market. Most of the selling (90%) was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)
$0
last 90 days
Sold
$1.4M
last 90 days
Net sold
22,300
$1.4M
DateInsiderWhatSharesPriceValueFiling
September 11, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 290 $58.94 $17.1K Form 4
September 11, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 475 $59.62 $28.3K Form 4
September 9, 2026 Charlton AlishaChief Financial Officer Sold 1,500 $61.05 $91.6K Form 4
September 9, 2026 Charlton AlishaChief Financial Officer Sold 800 $61.76 $49.4K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 2,160 $58.92 $127.3K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 2,691 $59.84 $161K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 4,274 $60.72 $259.5K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 1,157 $61.88 $71.6K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 935 $62.93 $58.8K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 2,144 $63.85 $136.9K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 300 $64.70 $19.4K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 806 $58.66 $47.3K Form 4
September 9, 2026 Van Kirk Richard Lee JrChief Executive Officer, Director Soldpre-planned (10b5-1) 4,768 $59.45 $283.5K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about PDEX

What does Pro Dex Inc do?

Pro Dex Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PDEX.

Is Pro Dex Inc profitable?

Yes. In fiscal 2026 it reported net income of $13.7M on revenue of $77.5M, a net margin of 17.6%.

How much revenue does Pro Dex Inc make?

In fiscal 2026 Pro Dex Inc reported revenue of $77.5M. That is 16.5% more than a year earlier.

When did Pro Dex Inc last report?

Its most recent periodic report is the annual report (10-K) filed on September 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 18, 2026.

Similar companies

MDLN
Medline Inc.
SYK
Stryker Corp
MMM
3M Co
BDX
Becton Dickinson & Co
BSX
Boston Scientific Corp
BAX
Baxter International Inc

Compare PDEX with

Compare PDEX with any company

Follow PDEX

Get an email when Pro Dex Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow PDEX: get an email when it files

Where the numbers come from

Financial figures are the values Pro Dex Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.